ASTROCYTOMA, IDH-MUTANT, GRADE 3
Clinical trials for ASTROCYTOMA, IDH-MUTANT, GRADE 3 explained in plain language.
Never miss a new study
Get alerted when new ASTROCYTOMA, IDH-MUTANT, GRADE 3 trials appear
Sign up with your email to follow new studies for ASTROCYTOMA, IDH-MUTANT, GRADE 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Drug attack on tough brain cancers
Disease control Not yet recruitingThis study is testing a new combination of two drugs, retifanlimab and DFMO, for people with aggressive brain tumors (high-grade gliomas) that have started growing again. The main goals are to find the safest dose of DFMO to use with retifanlimab and to see if the combination cha…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for brain cancer patients in major trial
Disease control Not yet recruitingThis study is testing if adding a new targeted drug, vorasidenib, to the usual treatment (radiation and chemotherapy) works better for people with a specific type of newly diagnosed brain tumor called grade 3 astrocytoma. About 408 participants will receive either the new drug co…
Matched conditions: ASTROCYTOMA, IDH-MUTANT, GRADE 3
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC